Association between APE1 Asp148Glu polymorphism and the risk of urinary cancers: a meta-analysis of 18 case–control studies

Abstract

BackgroundSeveral observational studies suggested that APE1 Asp148Glu was significantly associated with urinary cancers; however, the results of published studies are inconsistent.Materials and methodsThe PubMed and EMBASE were searched for case–control studies regarding the association between Asp148Glu and the risk of urinary cancers with a time limit of September 12, 2015. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association between Asp148Glu and the risk of developing prostate cancer, kidney cancer, bladder cancer, as well as all urinary cancers combined.ResultsA total of 18 case–control studies were included in the analysis. Our meta-analysis revealed that the inheritance of at least one APE1 148Glu among Asian men was associated with a 1.26-fold increase in the risk of developing urinary cancers. Meanwhile, APE1 Asp148Glu was significantly associated with the risk of prostate cancer. However, there were no significant relationships between the APE1 SNP (single nucleotide polymorphism) and all urinary cancers combined and bladder cancer and kidney cancer among the men of Caucasian/Asian/African descent or all racial/ethnic groups combined. When stratified by the quality score, no significant association was found in high-quality studies (score ≥7), but a significant increased risk of urinary cancers was observed in lower quality studies (score <7) (dominant model: OR=1.27, 95% CI=1.11–1.45).ConclusionOur meta-analysis suggests that APE1 Asp148Glu was not associated with the risk of urinary cancers but might increase the risk of urinary cancers among Asians. Stratification by cancer type identified a significant association of Asp148Glu with prostate cancer.

Investigation of APE1 and OGG1 expression in chronic hemodialysis patients

“…The results of investigations into the association between APE1 gene variations and kidney cancer susceptibility have produced con icting outcomes. In a meta-analysis conducted by Zhong et al, no signi cant in uence of APE1 polymorphism on urinary cancers susceptibility was observed [29]. Similarly, in a study led by Cao and colleagues, a polymorphism located within the promoter region, capable of in uencing gene expression, was not identi ed as a factor linked to kidney cancer [30].…”

“…Studies have demonstrated that in cases of acute renal injuries induced by oxidative stress, APE1 expression decreases, leading to the development of renal apoptosis [27]. APE1 is markedly upregulated in various cancer types, and its subcellular localization can vary signi cantly depending on the speci c tissue and stage of tumor development [13,29]. However, the causal relationship between APE1's overexpression and localization in tumors and their role in initiating and advancing cancer, increasing its aggressiveness, and promoting invasion remains a subject of ongoing debate.…”

Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients

“…It is not yet clear if family history plays a role in bladder cancer development. Research shows that the risk increases for first- and second-degree relatives, yet genetic predisposition is still under investigation [ 4 , 5 , 6 ]. Bladder cancer is usually presented with painless macrohematuria [ 7 ].…”